Healthy Subjects
Conditions
Brief summary
To assess the effect of consumption of an oral nutrition supplement on Arginine, a blood marker of nutritional intake
Interventions
Oral nutrition supplement intended for consumption at 3 servings per day
Sponsors
Société des Produits Nestlé (SPN)
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Healthy subject (absence of metabolic disorder, heart disease, endocrine disease, cancer) * Discontinued use of omega 3 fatty acid supplements - 10 days prior to testing * Willing to provide signed informed consent
Exclusion criteria
* Smoker * Patients with potential for non-compliance * Patients with allergy to ingredients in test products (i.e. milk protein, fish oil) * Subject who in the Investigator's assessment cannot be expected to comply with study protocol * Currently participating in another conflicting clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in plasma arginine levels in µmol/L | Pre-consumption, 30, 60, 120, 180, 240 minutes |
Secondary
| Measure | Time frame |
|---|---|
| Change in plasma-free phospholipid Eicosapentaenoic acid (EPA) in µg/ml | Pre-consumption, 30, 60, 120, 180, 240 minutes |
| Change in plasma phospholipid Eicosapentaenoic acid (EPA) in µg/ml | Pre-consumption, 30, 60, 120, 180, 240 minutes |
Other
| Measure | Time frame |
|---|---|
| Change in plasma-free phospholipid Docosahexaenoic acid (DHA) in µg/ml | Pre-consumption, 30, 60, 120, 180, 240 minutes |
| Change in plasma phospholipid Docosahexaenoic acid (DHA) in µg/ml | Pre-consumption, 30, 60, 120, 180, 240 minutes |
Outcome results
None listed